FIELD: biochemistry, hormones. SUBSTANCE: invention relates to pharmacologically active derivative of peptide hormone originating from native peptide hormone that is modified by introduction of lipophilic substituent Z at C-terminal amino acid of indicated peptide hormone or its analogue where indicated lipophilic substituent has from 8 to 20 carbon atoms. The end compounds relate to medicinal agents for treatment of patients with osteoporosis. EFFECT: valuable medicinal properties of hormone derivatives. 7 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE COMPOSITION CONTAINING PROPYLENE GLYCOL OPTIMAL FOR MANUFACTURING AND APPLICATION IN INJECTION DEVICES | 2004 |
|
RU2421238C2 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
| ANALOGUES OF EGF(A) WITH SUBSTITUENTS-FATTY ACIDS | 2017 |
|
RU2747877C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
| TOLEROGENIC DNA VACCINE | 2017 |
|
RU2752608C2 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| INSULIN DERIVATIVE, SOLUBLE PROLONGED PHARMACEUTICAL COMPOSITION, METHOD OF PROLONGATION OF HYPOGLYCAEMIC EFFECT IN TREATMENT OF DIABETIC PATIENTS | 1994 |
|
RU2164520C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
